Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-analysis revealed that the benefits of cetuximab were limited to patients with KRAS wild-type (wt) tumors.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“The results of this trial demonstrated a decrease in progression-free survival but no difference in overall survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“Some large clinical trials have shown that FOLFIRI (leucovorin + 5-FU + irinotecan) or FOLFOX regimens combined with EGFR inhibitors can benefit KRAS-WT CRC.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“However, CRC with KRAS mutations do not benefit from EGFR inhibitors, possibly because activation of KRAS does not depend upstream on EGFR [149,150,151,152].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“According to the CRYSTAL trial, the application of cetuximab and FOLFIRI in first-line treatment can reduce the risk of progression by 15% and increase overall survival (OS) by 8.2 months in patients who have KRAS WT mCRC compared with patients taking FOLFIRI alone [5].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [5]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Research works printed but not linked: 3
- Rougier P, 2004, J Clin Oncol, 22, 248s, 10.1200/jco.2004.22.14_suppl.3513 · doi:10.1200/jco.2004.22.14_suppl.3513
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Schilsky RL, 2002, Clin Cancer Res, 8, 935
Cited by
Items 801–900 of 1,017
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
Zlobec, I., Molinari, F., Martin, V., Mazzucchelli, L., Saletti, P., Trezzi, R., Dosso, S. D., Vlajnic, T., Frattini, M., & Lugli, A. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i38.4823 · Cited by 58
Advances in targeted and immunobased therapies for colorectal cancer in the genomic era
Seow, H. F., Yip, W. K., & Fifis, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95101 · Cited by 59
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors
Gelfo, V., Rodia, M. T., Pucci, M., Dall’Ora, M., Santi, S., Solmi, R., Roth, L. E., Lindzen, M., Bonafè, M., Bertotti, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12354 · Cited by 56
“EGFR antibodies in combination with chemotherapy prolong survival in subjects with mCRC and are a standard component of therapy of such individuals [9].”
BackgroundUpdate on current problems in colorectal liver metastasis
Chakedis, J., Squires, M. H., Beal, E. W., Hughes, T. M., Lewis, H. L., Paredes, A. Z., Al-Mansour, M. R., Sun, S., Cloyd, J. M., & Pawlik, T. M. (2017) · Current Problems in Surgery · doi:10.1067/j.cpsurg.2017.10.002 · Cited by 52
Tumour‐associated B cells in urothelial urinary bladder cancer
Zirakzadeh, A. A., Sherif, A. M., Rosenblatt, R., Bergman, E. A., Winerdal, M., Yang, D., Cederwall, J., Jakobsson, V., Hyllienmark, M., Winqvist, O., et al. (2019) · Scandinavian Journal of Immunology · doi:10.1111/sji.12830 · Cited by 58
Roberti, M. P., Barrio, M. M., Bravo, A. I., Rocca, Y. S., Arriaga, J. M., Bianchini, M., Mordoh, J., & Levy, E. M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1360-2 · Cited by 51
“For instance, activating mutations within K-RAS constitutively activates the RAS-signaling pathway and can predict resistance to anti-EGFR mAbs [8, 9].”
BackgroundOncogenic Kras Promotes Chemotherapy-Induced Growth Factor Shedding via ADAM17
Van Schaeybroeck, S., Kyula, J. N., Fenton, A., Fenning, C. S., Sasazuki, T., Shirasawa, S., Longley, D. B., & Johnston, P. G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0714 · Cited by 51
“Use of the EGFR-targeted monoclonal antibody cetuximab in first- and second-line treatment of advanced CRC patients has resulted in increased objective responses and progressionfree survival; however, this benefit is limited to patients with KrasWT tumors (25, 26).”
BackgroundCurable Metastatic Colorectal Cancer
Eadens, M., & Grothey, A. F. (2011) · Current Oncology Reports · doi:10.1007/s11912-011-0157-0 · Cited by 51
“Both of these studies showed significantly improved response rates and PFS but not OS [ 31 , 32].”
BackgroundInfluentialIdentification of the angiogenic gene signature induced by EGF and hypoxia in colorectal cancer
Khong, T. L., Thairu, N., Larsen, H., Dawson, P., Kiriakidis, S., & Paleolog, E. M. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-518 · Cited by 56
Halama, N., Spille, A., Lerchl, T., Brand, K., Herpel, E., Welte, S., Keim, S., Lahrmann, B., Klupp, F., Kahlert, C., et al. (2013) · OncoImmunology · doi:10.4161/onci.24116 · Cited by 50
“In addition, first-line therapies against CRC have been associated with rates are around 50–60%.(2,3) It is therefore crucial to identify parameters that predict chemotherapeutic responses in these patients.”
BackgroundFool’s gold, lost treasures, and the randomized clinical trial
Stewart, D. J., & Kurzrock, R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-193 · Cited by 53
“Across a range of colorectal cancer and NSCLC studies, p-value for association of response with mutation status was usually more significant than association of overall survival with mutation status (Table 1) [35,36,52-70], in keeping with increased statistical power with a response endpoint.”
BackgroundCiardiello, F., Tejpar, S., Normanno, N., Mercadante, D., Teague, T., Wohlschlegel, B., & Cutsem, E. V. (2011) · Targeted Oncology · doi:10.1007/s11523-011-0181-x · Cited by 53
Self-citationDamjanov, N., Weiss, J., & Haller, D. G. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0022 · Cited by 54
“The addition of bevacizumab improves response rates of combination chemotherapeutic regimens in most phase III trials [26–28], as does the addition of cetuximab [13, 14 , 29, 30].”
BackgroundInfluentialKim, H. S., Heo, J. S., Lee, J., Lee, J. Y., Lee, M.-Y., Lim, S. H., Lee, W. Y., Kim, S. H., Park, Y. A., Cho, Y. B., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2141-4 · Cited by 51
Mutation spectra of RAS gene family in colorectal cancer
Chang, Y.-Y., Lin, P.-C., Lin, H., Lin, J.-K., Chen, W.-S., Jiang, J., Yang, S.-H., Liang, W.-Y., & Chang, S. (2016) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2016.02.013 · Cited by 58
Wu, D., Lin, P.-L., Wang, L., Huang, C., & Lee, H. (2017) · Theranostics · doi:10.7150/thno.18175 · Cited by 55
“Unfortunately, relapses of metastatic colorectal cancer remain common, due to resistance to standard treatments that include chemotherapy, anti-angiogenesis therapies, and anti-EGFR monoclonal antibody treatments, administered singly or in combination (3-7).”
BackgroundSalvatore, L., Aprile, G., Arnoldi, E., Aschele, C., Carnaghi, C., Cosimelli, M., Maiello, E., Normanno, N., Sciallero, S., Valvo, F., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2016-000147 · Cited by 53
Hong, I., Hong, S. W., Chang, Y. G., Lee, W. Y., Lee, B.-M., Kang, Y. K., Kim, Y. S., Paik, I. W., & Lee, H. (2015) · Annals of Coloproctology · doi:10.3393/ac.2015.31.3.84 · Cited by 53
“New chemotherapeutic agents and targeted therapies have shown promising results of improving survival in colorectal cancer patients [4, 5].”
BackgroundLévi, F., Karaboué, A., Gorden, L. D., Innominato, P. F., Saffroy, R., Giacchetti, S., Hauteville, D., Guettier, C., Adam, R. A., & Bouchahda, M. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1327-8 · Cited by 54
Ahmed, S., Shahid, R. K., Leis, A. M., Haider, K., Kanthan, S. C., Reeder, B. A., & Pahwa, P. (2013) · Current Oncology · doi:10.3747/co.20.1469 · Cited by 50
Clinical benefit of surgery for stage IV colorectal cancer with synchronous peritoneal metastasis
Study Group for Peritoneal Metastasis from Colorectal Cancer by the Japanese Society for Cancer of the Colon and Rectum, Kobayashi, H., Kotake, K., Funahashi, K., Hase, K., Hirata, K., Iiai, T., Kameoka, S., Kanemitsu, Y., Maeda, K., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0820-3 · Cited by 54
“The development of multiagent chemotherapy and molecular-targeted drugs has improved the outcomes of patients with advanced colorectal cancer [35–44].”
BackgroundPredictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer
Luo, H., & Xu, R.-H. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3858 · Cited by 56
Siena, S., Glynne‐Jones, R., Adenis, A., Thaler, J., Preusser, P., Aguilar, E. A., Aapro, M., Loos, A. H., Esser, R., & Wilke, H. (2010) · Cancer · doi:10.1002/cncr.24945 · Cited by 52
“Number of previous treatment lines for mCRC 1 66 (16) 125 (18) 191 (17)”
BackgroundRusso, A. D., Rizzo, S., Bronte, G., Silvestris, N., Colucci, G., Gebbia, N., Bazan, V., & Fulfaro, F. (2009) · Oncology · doi:10.1159/000258497 · Cited by 52
“reported the first series of 48 chemonaive patients initially treated with single-agent cetuximab for 6 weeks and thereafter with cetuximab plus irinotecan with fluorouracil and folinic acid (FOLFIRI). In the cetuximab-alone part of this phase I/II study, patients with wild-type KRAS tumors had an ORR of 27.6p compare…”
InfluentialSong, H., Hedayati, M., Hobbs, R. F., Shao, C., Bruchertseifer, F., Morgenstern, A., DeWeese, T. L., & Sgouros, G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0108 · Cited by 48
“Few clinical trials have been launched partially due to the prevalent expression of EGFR on normal epithelial cells that lead to skin and gastrointestinal toxicity observed in cetuximab trials (43).”
BackgroundFrankel, T. L., Vakiani, E., Nathan, H., DeMatteo, R. P., Kingham, T. P., Allen, P. J., Jarnagin, W. R., Kemeny, N. E., Solit, D. B., & D'Angelica, M. I. (2016) · Cancer · doi:10.1002/cncr.30351 · Cited by 50
“Therapies targeting these pathways have been developed, and RAS mutational status has emerged as a major predictor of response to anti-epidermal growth factor receptor (anti-EGFR) therapies.(10,11)”
BackgroundGlockzin, G., Zeman, F., Croner, R. S., Königsrainer, A., Pelz, J. O. W., Ströhlein, M. A., Rau, B., Arnold, D., Koller, M. T., Schlitt, H. J., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.07.011 · Cited by 50
Masuishi, T., Tsuji, A., Kotaka, M., Nakamura, M., Kochi, M., Takagane, A., Shimada, K., Denda, T., Segawa, Y., Tanioka, H., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01042-w · Cited by 53
Dasari, A. N., Sobrero, A. F., Yao, J. C., Yoshino, T., Schelman, W. R., Yang, Z., Chien, C., Kania, M. K., Tabernero, J. M., & Eng, C. (2021) · Future Oncology · doi:10.2217/fon-2021-0202 · Cited by 56
KRAS Mutation Is a Predictor of Oxaliplatin Sensitivity in Colon Cancer Cells
Lin, Y., Liau, J., Yu, S.-C., Ou, D., Lin, L., Tseng, L., Chang, Y., Yeh, K., & Cheng, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050701 · Cited by 54
“Our study was initiated to find better predictors in current chemotherapy, for which the hypothesis was generated from subgroup analyses of randomized prospective clinical trials, PRIME [8] and OPUS [7], versus CRYSTAL [9].”
ResultMechanisms of colorectal liver metastasis development
Shasha, T., Gruijs, M., & van Egmond, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04630-6 · Cited by 57
“However, when patients have CRLM with mutated EGFR signaling pathways, antiEGFR mAbs are ineffective [139].”
BackgroundLin, Y., Wu, M.-H., Wei, T.-T., Chung, S.-H., Chen, K., Cheng, A., & Chen, C. (2012) · Neoplasia · doi:10.1596/neo.12300 · Cited by 49
“For example, overexpression of HER2 on trastuzumab treatment of breast cancer, distinct EGFR mutation on gefitinib treatment of NSCLC, and wild type k-ras on cetuximab treatment of colorectal cancer have been the paradigms of predictive biomarkers for molecular targeted therapy [32–34].”
Summary outcomes of two‐stage resection for advanced colorectal liver metastases
Chua, T. C., Liauw, W., Chu, F., & Morris, D. L. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23170 · Cited by 51
Dueland, S., Hagness, M., Line, P., Guren, T. K., Tveit, K. M., & Foss, A. E. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4137-0 · Cited by 52
Ålgars, A., Lintunen, M., Carpén, O., Ristamäki, R., & Sundström, J. T. T. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.223 · Cited by 60
Bengala, C., Bettelli, S. R., Bertolini, F., Sartori, G., Fontana, A., Malavasi, N., Depenni, R., Zironi, S., Giovane, C. D., Luppi, G., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605853 · Cited by 53
“…has been shown to be a predictive factor for response to anti-EGFR monoclonal antibodies in metastatic colorectal cancer (Bokemeyer et al , 2009; Van Cutsem et al , 2009) and, recently, KRAS wild-type status has been recognised by the US FDA and EMEA as a predictive factor to select patients…”
Monoclonal antibodies: potential new therapeutic treatment against multiple myeloma
Allegra, A., Penna, G., Alonci, A., Russo, S., Greve, B., Innao, V., Minardi, V., & Musolino, C. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12107 · Cited by 52
“Cetuximab is approved for the treatment of metastatic colorectal cancer and relapsed/metastatic head-and-neck-cancer and other epithelial malignancies (220, 221).”
BackgroundAnti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases
Feng, Q., Wei, Y., Chen, J., Chang, W., Ye, L., Zhu, D., & Xu, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4263 · Cited by 58
Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status
Modest, D. P., Stintzing, S., Laubender, R. P., Neumann, J. H. L., Jung, A., Giessen, C. A., Haas, M., Aubele, P., Schulz, C. U., Boeck, S. H., et al. (2011) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283493160 · Cited by 53
Correlation Between PET/CT Parameters and KRAS Expression in Colorectal Cancer
Chen, S.-W., Chiang, H.-C., Chen, W. T., Hsieh, T., Yen, K., Chiang, S., & Kao, C. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000481 · Cited by 55
“Two studies have shown that anti-EGFR monoclonal antibodies have significant efficacy in the treatment of metastatic CRC patients with wild-type KRAS tumors.(13,14) TABLE 2.”
BackgroundBonnetain, F., Borg, C., Adams, R., Ajani, J. A., Benson, A. B., Bleiberg, H., Chibaudel, B., Díaz‐Rubio, E., Douillard, J., Fuchs, C. S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx191 · Cited by 58
Tan, K. M. L., Leong, S. M., Kee, Z., Caramat, P. V., Teo, J., Blanco, M. V. M., Koay, E. S., Cheong, W. K., Soh, T. I. P., Yong, W. P., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.02.039 · Cited by 50
Pal, D., Tyagi, A., Chandrasekaran, B., Alatassi, H., Ankem, M. K., Sharma, A. K., & Damodaran, C. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0810-8 · Cited by 51
Li, J., & Qi, Y. (2019) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2019.01.003 · Cited by 53
RetractedMartin, S. Z., Wagner, D., Hörner, N., Horst, D. A., Lang, H., Tagscherer, K. E., & Roth, W. (2019) · BMC Cancer · doi:10.1186/s12885-019-6270-4 · Cited by 60
Molecular Targets for the Treatment of Metastatic Colorectal Cancer
Cohen, R., Pudlarz, T., Delattre, J.-F., Colle, R., & André, T. (2020) · Cancers · doi:10.3390/cancers12092350 · Cited by 57
van Houdt, W. J., Hoogwater, F. J. H., de Bruijn, M. T., Emmink, B. L., Nijkamp, M. W., Raats, D. A. E., van der Groep, P., van Diest, P., Borel Rinkes, I. H. M., & Kranenburg, O. (2010) · Neoplasia · doi:10.1593/neo.92088 · Cited by 50
“EGFR-targeting therapeutics have shown promising clinical activity in a minority of colorectal cancer patients [8–12].”
BackgroundSaki, M. R., Toulany, M., & Rodemann, H. P. (2013) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.06.023 · Cited by 50
“K-RAS mutations that result in the constitutive activation of K-Ras are one of the most important predictive markers for the lack of a tumor cell response to cetuximab, as shown for colorectal cancer [41,43,44].”
BackgroundLiu, Z., Zhang, Y., Dang, Q., Wu, K., Jiao, D., Li, Z., Sun, Z., & Han, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.632430 · Cited by 54
“Elegant efforts have demonstrated multifarious genomic alterations were critical to the prognosis and target therapy of CRC[31-35].”
BackgroundStanding, D., Dandawate, P. R., & Anant, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1112987 · Cited by 52
“Specific examples of successful monoclonal antibody therapies targeted epidermal growth factor receptor (EGFR) (75, 78), C-MET (79), HER2 (80), fibroblast activation protein (FAP) (81), and cytotoxic T lymphocyte-associated antigen 4 (CTLA4) (82).”
BackgroundOpportunities and challenges provided by crosstalk between signalling pathways in cancer
Prahallad, A., & Bernards, R. (2015) · Oncogene · doi:10.1038/onc.2015.151 · Cited by 54
Perkins, G., Lièvre, A., Ramacci, C., Méatchi, T., de Reynies, A., Emile, J., Boige, V., Tomasic, G., Bachet, J., Bibeau, F., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25152 · Cited by 49
“A survival benefit of a combination of chemotherapy plus cetuximab over chemotherapy alone was more recently reported in first-line in 2 randomized studies.(4,5) Similar results have been obtained with the fully human IgG2 antiEGFR monoclonal antibody panitumumab which was associated with a higher response rate and a…”
ResultShin, B. J., Burkhardt, J., Riina, H. A., & Boockvar, J. A. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.01.008 · Cited by 48
Iida, M., Brand, T. M., Campbell, D. A., Starr, M. M., Luthar, N., Traynor, A. M., & Wheeler, D. L. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.24342 · Cited by 52
Lyberopoulou, A., Aravantinos, G., EFSTATHOPOULOS, E. P., Nikiteas, N. I., Bouziotis, P., Isaakidou, A., Papalois, A. E., Marinos, E., & Gazouli, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123902 · Cited by 52
Chemoembolization in colorectal liver metastases: the rebirth.
Fiorentini, G., Aliberti, C., Mulazzani, L., Coschiera, P., Catalano, V., Rossi, D., Giordani, P., & Ricci, S. (2014) · PubMed · Cited by 48
Modest, D. P., Jung, A., Moosmann, N., Laubender, R. P., Giessen, C. A., Schulz, C. U., Haas, M., Neumann, J. H. L., Boeck, S. H., Kirchner, T., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26467 · Cited by 56
“However, no precise information of the different subtypes of KRAS mutation has been published from the CRYSTAL, the OPUS and the CECOG trial yet.(3,17,19) Poor outcome data for patients with KRAS mutant mCRC were also published for the PRIME-Study (15.”
BackgroundLahti, S. J., Xing, M., Zhang, D., Lee, J. J., Magnetta, M. J., & Kim, H. S. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2015.05.032 · Cited by 50
Graziani, V., Scognamiglio, M., Belli, V., Esposito, A., D’Abrosca, B., Chambery, A., Russo, R., Panella, M., Russo, A., Ciardiello, F., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23704-9 · Cited by 57
Garlipp, B., Gibbs, P., Hazel, G. A. V., Jeyarajah, R., Martin, R. C. G., Bruns, C. J., Lang, H., Manas, D., Ettorre, G. M., Pardo, F., et al. (2019) · British journal of surgery · doi:10.1002/bjs.11283 · Cited by 48
Dendritic cell vaccine therapy for colorectal cancer
Wooster, A. L., Girgis, L. H., Brazeale, H., Anderson, T. S., Wood, L. M., & Lowe, D. B. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2020.105374 · Cited by 48
“vascular endothelial growth factor (VEGF) (bevacizumab [Avastin®]) antibodies [9].”
BackgroundYu, I. S., & Cheung, W. Y. (2018) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2018/9450754 · Cited by 47
Wu, Y., Wen, H., Bernstein, Z. J., Hainline, K. M., Blakney, T. S., Congdon, K. L., Snyder, D. J., Sampson, J. H., Sanchez-Perez, L. A., & Collier, J. H. (2022) · Science Advances · doi:10.1126/sciadv.abm7833 · Cited by 51
Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer
Gonzalez, N. S., Ros, J., Baraibar, I., Salvà, F., Rodríguez-Castells, M., Alcaráz, A., García, A., Tabernero, J. M., & Élez, E. (2024) · Cancers · doi:10.3390/cancers16020412 · Cited by 57
Guedes, J. G., Veiga, I., Rocha, P., Pinto, P., Pinto, C., Pinheiro, M., Peixoto, A., Fragoso, M., Raimundo, A. C., Ferreira, P., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-169 · Cited by 51
Role of genetics in prediction of disease course and response to therapy
Vermeire, S., Assche, G. V., & Rutgeerts, P. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i21.2609 · Cited by 54
Controversies in the oncosurgical management of liver limited stage IV colorectal cancer
Jones, R. P., Stättner, S., Sutton, P. A., Dunne, D. F. J., McWhirter, D., Fenwick, S. W., Malik, H. M. A., & Poston, G. J. (2014) · Surgical Oncology · doi:10.1016/j.suronc.2014.02.002 · Cited by 49
“The phase III CRYSTAL trial [18] reported median”
BackgroundPatterson, S. D., Cohen, N., Karnoub, M., Truter, S. L., Emison, E., Khambata‐Ford, S., Spear, B. B., Ibia, E. O., Sproule, R., Barnes, D. M., et al. (2011) · Pharmacogenomics · doi:10.2217/pgs.11.52 · Cited by 48
Banck, M. S., & Grothey, A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0188 · Cited by 48
“Most likely because of the high rate of cross-over from BSC to panitumumab upon progression (75% of patients), no statistically significant prolongation of overall survival was found for panitumumab in KRAS-wt CRC. Retrospective analysis of KRAS mutational status from tumor tissue from several randomized phase III tri…”
BackgroundDNA Sequencing of Cancer: What Have We Learned?
Chmielecki, J., & Meyerson, M. M. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-060712-200152 · Cited by 52
Resection of Liver Metastases in Colorectal Cancer in the Era of Expanding Systemic Therapy
Jones, R. P., & Poston, G. J. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-062415-093510 · Cited by 48
Targeted therapy and elderly people: A review
Daste, A., Chakiba, C., Domblides, C., Gross‐Goupil, M., Quivy, A., Ravaud, A., & Soubeyran, P. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.10.005 · Cited by 52
Fumet, J.-D., Isambert, N., Hervieu, A., Zanetta, S., Guion, J.-F., Hennequin, A., Rederstorff, E., Bertaut, A., & Ghiringhelli, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000375 · Cited by 48
Simillis, C., Kalakouti, E., Afxentiou, T., Kontovounisios, C., Smith, J. J., Cunningham, D., Adamina, M., & Tekkis, P. P. (2019) · World Journal of Surgery · doi:10.1007/s00268-019-04984-2 · Cited by 48
Hamers, P. A. H., Elferink, M. A. G., Stellato, R. K., Punt, C. J. A., May, A. M., Koopman, M., & Vink, G. R. (2020) · International Journal of Cancer · doi:10.1002/ijc.33200 · Cited by 54
“Since 2012, however, clinical trial results of mCRC patients receiving first-line systemic therapy suggest a strong improvement in median OS to over 30 months.(3-7) This substantial improvement in median OS does not cor-”
BackgroundThe Timing of Chemotherapy and Surgery for the Treatment of Colorectal Liver Metastases
Nordlinger, B., Vauthey, J., Poston, G. J., Benoist, S., Rougier, P. R., & Cutsem, E. V. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.031 · Cited by 48
Self-citationMahmood, S. F., Gruel, N., Nicolle, R., Chapeaublanc, E., Delattre, O., Radvanyi, F., & Bernard‐Pierrot, I. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.028 · Cited by 47
Winder, T., Zhang, W., Yang, D., Ning, Y., Bohanes, P., Gerger, A., Wilson, P. M., Pohl, A., Mauro, D. J., Langer, C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2092 · Cited by 46
“Activating KRAS mutation has recently emerged as major predictor of resistance to the EGFR-targeted MoAbs and patient selection based on KRAS mutational status allows more accurate treatment selection with improved efficacy, reduction of unnecessary toxicities, and improved overall cost effectiveness (5, 6).”
Watanabe, T., Yoshino, T., Uetake, H., Yamazaki, K., Ishiguro, M., Kurokawa, T., Saijo, N., Ohashi, Y., & Sugihara, K. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt062 · Cited by 46
Bando, H., Yoshino, T., Shinozaki, E., Nishina, T., Yamazaki, K., Yamaguchi, K., Yuki, S., Kajiura, S., Fujii, S., Yamanaka, T., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-405 · Cited by 53
“; licensee BioMed Central Commons Attribution License (http://creativec reproduction in any medium, provided the or and Japan have recommended compulsory KRAS mutation testing before treatment [1-6].”
BackgroundChen, J., Ye, Y., Sun, H., & Shi, G. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-2005-9 · Cited by 48
Hartman, D. J., Davison, J. M., Foxwell, T. J., Nikiforova, M. N., & Chiosea, S. I. (2012) · International Journal of Cancer · doi:10.1002/ijc.27461 · Cited by 47
Huang, J., Nair, S., Mahoney, M. R., Nelson, G. D., Shields, A. F., Chan, E. W., Goldberg, R. M., Gill, S., Kahlenberg, M. S., Quesenberry, J. T., et al. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.12.002 · Cited by 52
Monoclonal antibodies against EGFR in non-small cell lung cancer
Pirker, R., & Filipits, M. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.10.008 · Cited by 51
Bruera, G., Santomaggio, A., Cannita, K., Baldi, P. L., Tudini, M., Galitiis, F. D., Mancini, M., Marchetti, P., Antonucci, A., Ficorella, C., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-567 · Cited by 46
“In Cetuximab-containing associations [29,30], metastasectomies were performed in 7% and 4.”
BackgroundResultBando, H., Yoshino, T., Tsuchihara, K., Ogasawara, N., Fuse, N., Kojima, T., Tahara, M., Kojima, M., Kaneko, K., Doi, T., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.247 · Cited by 50
“%) as per various mutation detection methods, including ARMS/S, and thus support the validity of our direct sequencing procedure (Amado et al, 2008; Karapetis et al, 2008; Tol et al, 2009; Van Cutsem et al, 2009).”
BackgroundMethodResultInfluentialMetzger, B., Chambeau, L., Begon, D. Y., Faber, C., Kayser, J., Berchem, G., Pauly, M., Boniver, J., Delvenne, P., Dicato, M. A., et al. (2011) · BMC Medical Genetics · doi:10.1186/1471-2350-12-144 · Cited by 56
“with a wild type K-ras won’t benefit from the use of these monoclonal antibodies[5-7].”
BackgroundExploring Different Strategies for Efficient Delivery of Colorectal Cancer Therapy
Lin, C., Ng, H., Pan, W., Chen, H., Zhang, G., Bian, Z., Lü, A., & Yang, Z. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161125995 · Cited by 53
“survival [91,92].”
Suenaga, M., Mashima, T., Kawata, N., Wakatsuki, T., Horiike, Y., Matsusaka, S., Dan, S., Shinozaki, E., Seimiya, H., Mizunuma, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9187 · Cited by 49
IGF1R and c-met as therapeutic targets for colorectal cancer
Shali, H., Ahmadi, M., Kafil, H. S., Dorosti, A., & Yousefi, M. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.05.034 · Cited by 46
Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding
Baltruškevičienė, E., Schveigert, D., Stankevičius, V., Mickys, U., Žvirblis, T., Bublevič, J., Sužiedėlis, K., & Aleknavičius, E. (2017) · BMC Cancer · doi:10.1186/s12885-017-3575-z · Cited by 46
“Only a few tumor markers (RAS and BRAF mutation, mismatch repair status) have been implemented into clinical practice [2, 3].”
Autophagy: A Versatile Player in the Progression of Colorectal Cancer and Drug Resistance
Manzoor, S., Muhammad, J. S., Maghazachi, A. A., & Hamid, Q. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.924290 · Cited by 45
Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection
Power, D. G., & Kemeny, N. E. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.08.001 · Cited by 47
“[20] Van Cutsem E, Kohne CH, Hitre E, et al.”
BackgroundInfluentialTargeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives
Hohla, F., Winder, T., Greil, R., Rick, F. G., Block, N. L., & Schally, A. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i20.6102 · Cited by 46
Meeting the biologic challenge of colorectal metastases
Wanebo, H. J., LeGolvan, M. P., Paty, P. B., Saha, S., Zuber, M., D'Angelica, M. I., & Kemeny, N. E. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9517-x · Cited by 50
“5 months) were statistically significantly influenced by the addition of Cetuximab and had increased toxicities [24].”
BackgroundA view on EGFR-targeted therapies from the oncogene-addiction perspective
Pérez, R., Crombet, T., de León, J., & Moreno, E. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00053 · Cited by 50
“This antibody is also indicated for Kras mutation-negative (wildtype), EGFR-expressing, metastatic colorectal cancer (mCRC) in combination with FOLFIRI for first-line treatment (Van Cutsem et al., 2009).”
BackgroundInfluentialHu‐Lieskovan, S., Vallböhmer, D., Zhang, W., Yang, D., Pohl, A., LaBonte, M. J., Grimminger, P., Hölscher, A. H., Semrau, R., Arnold, D., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2666 · Cited by 49
Glockzin, G., Rochon, J., Arnold, D., Lang, S. A., Klebl, F. H., Zeman, F., Koller, M. T., Schlitt, H. J., & Piso, P. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-67 · Cited by 48
Eng, C. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0167 · Cited by 45
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
Wurz, G. T., Kao, C.-J., & DeGregorio, M. W. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015615514 · Cited by 53
Metadata
- Authors
- Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P.
- Affiliations
- Klinikum Oldenburg (DE)
- Moscow City Oncology Hospital №62 (RU)
- Petz Aladár Megyei Oktató Kórház (HU)
- National University Hospital (SG)
- Yonsei University (KR)
- University Hospital Carl Gustav Carus (DE)
- University of the Witwatersrand (ZA)
- Merck KGaA, Darmstadt (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Hôpital Ambroise-Paré (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-02
- Volume
- 360
- Issue
- 14
- Pages
- 1408-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095201384
- Cited by
- 3,877
- References
- 34
- Citations by year
- 2026: 83 · 2025: 87 · 2024: 105 · 2023: 136 · 2022: 169 · 2021: 173 · 2020: 194 · 2019: 199 · 2018: 172 · 2017: 221 · 2016: 275 · 2015: 307 · 2014: 337 · 2013: 328 · 2012: 331
- FWCI
- 179.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, FOLFIRI, metastatic colorectal cancer, first-line therapy, KRAS mutation status, epidermal growth factor receptor, progression-free survival, overall survival, treatment response, adverse events, irinotecan, 5-fluorouracil, leucovorin, skin reactions, diarrhea, infusion reactions, anti-EGFR therapy
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Disease Progression, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.